Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zelicapavir · EDP-938

Small molecule · developed by Enanta Pharmaceuticals

Phase 2 Most advanced trial
ENTA Developer
4 Registered trials

What is Zelicapavir?

Zelicapavir (EDP-938) is an orally administered agent studied in respiratory syncytial virus (RSV) infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
EDP-938
Drug type
Small molecule
Therapy area
Infectious disease
Developer
Enanta Pharmaceuticals, Inc (ENTA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
U4OI721DMD

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07482657 Phase 2 RSV Infection Recruiting ENTA
NCT05568706 Phase 2 RSV Infection Completed ENTA
NCT03691623 Phase 2 RSV Infection Completed ENTA
NCT06601192 Phase 1 RSV Infection Completed ENTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Respiratory Syncytial Virus (RSV)RSVQTc IntervalRSV Infection

More from Enanta Pharmaceuticals

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ENTA page.

Follow ENTA, the company behind Zelicapavir

See ENTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ENTA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.